Ischaemic heart disease, chronic stable angina, chronic stable heart failure Circulatory System
Conditions
Interventions
All patients will receive EECP typically involving 35 x 1-h sessions of counterpulsations over a 7-week period.
Sponsors
Piyavate Hospital (Thailand)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, age >18 years 2. Patients with refractory angina, chronic stable angina or chronic stable heart failure 3. Willing to participate in the study with informed consent
Exclusion criteria
Exclusion criteria: 1. Patient with the diagnosis of congestive heart failure within 1 month prior to study entry 2. Patient with the diagnosis of acute coronary syndrome within 1 month prior to study entry 3. Patient with uncontrolled blood pressure (>180/110 mmHg) 4. Patient with cardiac arrhythmia (e.g. atrial fibrillation or atrial flutter or frequent premature ventricular contractions) that may interfere with triggering of EECP system 5. Patients with severe lower extremity vaso-occlusive disease 6. Patients with end stage renal disease requiring renal replacement therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum cystatin C All primary and secondary outcome measures will be assessed before and within 1 month, and 5-7 months after completion of EECP treatment of 35 sessions. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Calculated glomerular filtration rate (GFR) 2. Serum N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP) 3. Ejection fraction determined by echocardiography All primary and secondary outcome measures will be assessed before and within 1 month, and 5-7 months after completion of EECP treatment of 35 sessions. | — |
Countries
Thailand
Outcome results
None listed